GLP-1 drugs for weight loss, explained: what Ozempic, Wegovy and Mounjaro actually do

If you have heard the names Ozempic, Wegovy or Mounjaro and felt unsure where one drug stops and the next begins, you are not alone. They belong to a single family of prescription medicines that change how hungry you feel and how full you stay after eating. They are clinical tools, not lifestyle shortcuts, and every individual decision about them belongs with a doctor who knows your history.

This is a plain explainer of what these drugs are, who they are approved for, what the trials actually show, and the real trade-offs. It is not a how-to, and it does not cover dosing or where to get them.

What a GLP-1 drug actually is

GLP-1 stands for glucagon-like peptide-1, a hormone your gut releases after you eat. These medicines are receptor agonists, which means they mimic that natural hormone and switch on the same receptors it does.

That mimicry works on two fronts. Centrally, the drugs act on appetite and satiety circuits in the hypothalamus and brainstem, so hunger signals quieten down. Peripherally, they slow how fast your stomach empties, so you feel full sooner and stay full for longer.

There is an important sub-distinction. Some of these drugs target only the GLP-1 pathway. Others are "dual agonists" that also activate a second receptor called GIP, short for glucose-dependent insulinotropic polypeptide. Hitting two pathways instead of one is associated with a larger average effect on appetite and weight.

How they make you eat less

This is the part people most often get wrong. These are not stimulant appetite-suppressant pills like the diet aids sold over the counter. They are hormone-mimicking drugs, mostly injectable, that work through your body's own satiety machinery.

The brain side reduces how much you want to eat in the first place. The gut side, slowed stomach emptying, means a normal-sized meal sits with you longer, so you reach for less between meals. Together that produces a smaller calorie intake without the white-knuckle willpower most diets demand.

That mechanism is also why the most common side effects are digestive, and why food can feel less appealing on these drugs than it used to.

The brand-name decoder

The confusion is mostly about marketing names sitting on top of two active ingredients.

Semaglutide is the active ingredient in Ozempic and Rybelsus, both approved for type 2 diabetes, and in Wegovy, approved for weight management. Semaglutide is a single GLP-1 agonist.

Tirzepatide is the active ingredient in Mounjaro, approved for type 2 diabetes, and Zepbound, approved for weight management. Tirzepatide is the dual GLP-1/GIP agonist, which is tied to its larger average weight-loss effect.

So the headline split is simple: semaglutide products (Ozempic, Rybelsus, Wegovy) versus tirzepatide products (Mounjaro, Zepbound), with one brand per ingredient aimed at diabetes and another aimed at weight.

What the trials actually show

The efficacy numbers are genuinely large, but they come from supervised trials run alongside diet and activity changes.

The clearest comparison is SURMOUNT-5, a head-to-head trial in adults with obesity or overweight but without diabetes, with results announced in December 2024. At 72 weeks, tirzepatide produced an average 20.2% body-weight loss against 13.7% with semaglutide, roughly 22.8 kg versus 15.0 kg, about 47% greater relative weight loss. On tirzepatide, 31.6% of people reached at least 25% weight loss, versus 16.1% on semaglutide. Gastrointestinal effects were the most common adverse events for both, and GI-related discontinuations were higher with semaglutide at 5.6% than tirzepatide at 2.7%.

At 72 weeks tirzepatide produced an average 20.2% body-weight loss against 13.7% with semaglutide.SURMOUNT-5, 2024

The benefits now reach beyond the scale. In the SELECT trial of 17,604 adults with existing cardiovascular disease and overweight or obesity but no diabetes, once-weekly semaglutide cut major cardiovascular events, meaning cardiovascular death, non-fatal heart attack and non-fatal stroke, by 20% over a mean of about 40 months. That was the first obesity-drug trial with a positive cardiovascular outcome. In 2024 Wegovy was approved to reduce that cardiovascular risk in people with cardiovascular disease plus obesity or overweight, and Zepbound was approved for moderate-to-severe obstructive sleep apnoea in adults with obesity.

Who they are approved for

These are prescription-only medicines, and the approvals are specific. Wegovy (semaglutide 2.4 mg) is approved for adults with a BMI of 30 or higher, or 27 or higher with at least one weight-related condition such as hypertension, type 2 diabetes or high cholesterol, and for adolescents aged 12 and older with obesity. It is approved for use alongside a reduced-calorie diet and increased activity.

That last clause matters and busts a common myth. You do not need diabetes to qualify for weight-management use, and you do not get to skip the diet-and-activity part. Every approval is written as a combination with lifestyle change, not a replacement for it. The prescription gate also exists for safety: a clinician screens for the histories that make these drugs unsafe before anyone starts.

The real trade-offs

The most common side effects are gastrointestinal, nausea, vomiting, diarrhoea, constipation and stomach pain, and they tend to be worst when starting or after a dose increase.

The rarer but serious risks flagged on the labels include pancreatitis and gallbladder disease or gallstones, the latter more common with rapid weight loss. There is also a boxed warning for thyroid C-cell tumours based on rodent data, which is why the drugs are contraindicated for people with a personal or family history of medullary thyroid carcinoma or the MEN 2 syndrome. This is exactly the screening that an unregulated or compounded source skips, which is part of why a prescription matters.

Muscle loss is the trade-off people underestimate. A meaningful share of the weight lost, commonly cited as roughly 25% to 40%, is lean (fat-free) mass. The nuance: much of that is the normal consequence of rapid weight loss, not a unique drug effect, and it does not mean the weight loss is "fake". It can be blunted substantially. Guidance centres on protein intake above about 1.2 g per kg of body weight per day, spread across meals, plus structured resistance training. One real-world cohort with those supports lost about 13% of body weight but only about 3% of muscle mass over six months.

Then there is what happens when you stop. In the STEP 1 trial extension, participants lost a mean 17.3% of body weight by week 68 on semaglutide, but after stopping they regained about two-thirds of it, for a net loss of roughly 5.6% from baseline by week 120. Cardiometabolic improvements largely reverted too. The takeaway is not that all the loss vanishes overnight, many people stay below their starting weight, but that these behave like chronic therapies. Clinical guidance on how to stop without rebound is still limited, which is one more reason this is a decision to make with a doctor rather than alone.

Bottom line

GLP-1 and dual GLP-1/GIP drugs work by quieting appetite and slowing the stomach, and the trial results are large, but they are prescription-only medicines used alongside diet, protein and training, not instead of them.

Not a shortcut, and not medical advice

It is tempting to read 20% weight loss and conclude the food and the gym no longer matter. The trials say the opposite. The results come on top of a reduced-calorie diet and more activity, and it is protein plus resistance training that protect your muscle while the fat comes off.

These are not supplements you can safely buy online, and compounded or "research" versions bypass both quality control and the medical screening that makes the drugs safe to use. If you are weighing one up, the right next step is a conversation with a qualified clinician, not a checkout page.

This article is informational coverage, not medical advice, and it deliberately contains no dosing or sourcing guidance. GLP-1 medicines are prescription-only and carry real risks. Talk to a doctor or another qualified healthcare professional about whether any of this applies to you before making any decision about these drugs.

Sources

The Catalyst Feed

Content TeamIndependent, hands-on coverage of health, fitness & the tech that tracks it. Reviews you can trust — no hype.

#glp-1 #semaglutide #tirzepatide #weight-loss #ozempic #wegovy #mounjaro #prescription-drugs